Boule Diagnostics signs agreement to sell clinical chemistry systems in USA

Boule Diagnostics AB has signed a distribution agreement with the American company Medica Corporation Inc., to promote and sell their EasyRA® product in the United States.

EasyRA® is a system for clinical chemistry used to assist in patient diagnosis and determine problems, related to for example liver, kidney function and high cholesterol levels. The product is cleared for marketing by the FDA, the US Food and Drug Administration. Boule will begin marketing the product in the first quarter 2016.

“The decentralized market for in-vitro diagnostics is expanding in the United States. Cooperation with Medica, through the sale and distribution of their product EasyRA®, means that we can now offer our end customers the combination of hematology and chemistry systems they are looking for. This increases our ability to continue to gain market share in the US market, the world’s largest in-vitro diagnostics market,” says Ernst Westman, President and CEO, Boule Diagnostics AB.

“With the United States well-established brands, Medonic and CDS, Boule is an ideal partner for us. Our products complement each other very well. Furthermore, Boule is well established in the major US distribution channels and their products have a good reputation by their high quality and reliability,” says Robert Hagopian, CEO, Medica Corporation.

For more information, please contact:

Ernst Westman, President and CEO Boule Diagnostics AB, tel +46 708 60 88 63

About Boule Diagnostics AB (publ) 


Boule Diagnostics AB is a rapidly growing diagnostics company that develops, manufactures and markets systems and consumables for blood cell counts (hematology) outpatient care. The company is primarily oriented to small and medium sized hospitals, clinics and laboratories within outpatient care, and to other diagnostics companies within both human and veterinary hematology. The company operates via subsidiary companies in Sweden, USA and China. Boule Diagnostics shares have been listed on the NASDAQ Stockholm Exchange since 2011. Additional information about Boule can be found at http://www.boule.se.

About Medica Corporation Inc.

Based in Bedford, Massachusetts, Medica Corporation uses its proprietary technology to manufacture easy-to-use, low-cost diagnostic analyzers for testing blood, serum, and plasma.  The analyzers are uniquely easy to operate and service, and can be used routinely by personnel with a wide range of skill levels in hospital laboratories and physician’s offices. Additional information about Medica can be found at http://www.medicacorp.com.

Boule Diagnostics AB is required to publish the information in this press release by the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information is embargoed for publication until 08:30 (CET) on January 18, 2016.

Release